

FORM 1449 INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.171USCS	Application Number: 10/022,609
	Applicant: VANDLEN ET AL.	
	Filing Date: DECEMBER 17, 2001	Group Art Unit: 1647

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PCN	4,816,567	03/28/1989	CABILLY ET AL.			
↓	5,578,482	11/26/1996	LIPPMAN ET AL.			

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
PCN	9107566.3	04/10/1991	GB				
↓	WO 92/20798	11/26/1992	DET WIPD	/			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
- considered, but NOT publications, so will NOT BE included printed on face of patent +		Paper No. 7 dated March 20, 1995 from the history of Serial No. 08/096,277, now U.S. Patent No. 5,578,482, authored by Lawrence H. Rosorsko, publicly available as of the issue date of the patent of November 26, 1996
		Paper No. 8 dated June 29, 1995 from file history of Serial No. 08/096,277, now U.S. Patent No. 5,578,482, authored by U.S. PTO Examiner, publicly available as of issue date of the patent of November 26, 1996
PCN		Lupu, R. et al., "The role of erbB2 signal transduction pathways in human breast cancer", <i>Breast Cancer Research and Treatment</i> , 27:83-93 (1993)

23552

PATENT TRADEMARK OFFICE

NOTE "publicly available" is NOT equivalent to publications.

EXAMINER	Prayan	DATE CONSIDERED	5/12/05
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			